Free Trial

Addus HomeCare (NASDAQ:ADUS) Earns Market Outperform Rating from JMP Securities

Addus HomeCare logo with Medical background

JMP Securities restated their market outperform rating on shares of Addus HomeCare (NASDAQ:ADUS - Free Report) in a report issued on Wednesday morning,Benzinga reports. They currently have a $150.00 price objective on the stock.

A number of other research firms have also weighed in on ADUS. Macquarie reissued an "outperform" rating and issued a $133.00 target price on shares of Addus HomeCare in a report on Tuesday, June 10th. Wall Street Zen raised shares of Addus HomeCare from a "hold" rating to a "buy" rating in a research note on Sunday, June 29th. Seven investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Buy" and an average price target of $142.57.

View Our Latest Research Report on ADUS

Addus HomeCare Price Performance

Shares of Addus HomeCare stock traded down $2.05 during trading on Wednesday, reaching $107.64. 35,439 shares of the stock traded hands, compared to its average volume of 165,456. Addus HomeCare has a 52-week low of $88.96 and a 52-week high of $136.72. The company has a debt-to-equity ratio of 0.20, a current ratio of 1.74 and a quick ratio of 1.74. The business has a fifty day simple moving average of $112.52 and a two-hundred day simple moving average of $110.14. The company has a market capitalization of $1.98 billion, a price-to-earnings ratio of 24.34, a P/E/G ratio of 1.54 and a beta of 0.81.

Addus HomeCare (NASDAQ:ADUS - Get Free Report) last announced its quarterly earnings results on Monday, May 5th. The company reported $1.42 EPS for the quarter, beating analysts' consensus estimates of $1.33 by $0.09. Addus HomeCare had a return on equity of 9.23% and a net margin of 6.52%. The company had revenue of $337.71 million during the quarter, compared to analyst estimates of $341.66 million. During the same period in the prior year, the company earned $1.21 earnings per share. The firm's revenue was up 20.3% on a year-over-year basis. Sell-side analysts expect that Addus HomeCare will post 4.59 EPS for the current year.

Insider Activity

In other news, EVP Michael D. Wattenbarger sold 2,045 shares of the company's stock in a transaction that occurred on Tuesday, May 27th. The stock was sold at an average price of $115.00, for a total transaction of $235,175.00. Following the transaction, the executive vice president owned 7,796 shares of the company's stock, valued at approximately $896,540. This represents a 20.78% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Company insiders own 4.60% of the company's stock.

Hedge Funds Weigh In On Addus HomeCare

Several hedge funds have recently bought and sold shares of the business. Natixis lifted its position in shares of Addus HomeCare by 111.9% during the fourth quarter. Natixis now owns 250 shares of the company's stock worth $31,000 after purchasing an additional 132 shares during the last quarter. BI Asset Management Fondsmaeglerselskab A S purchased a new position in Addus HomeCare in the 1st quarter worth about $41,000. Meeder Asset Management Inc. bought a new stake in Addus HomeCare during the 4th quarter valued at about $77,000. Harvest Fund Management Co. Ltd purchased a new stake in Addus HomeCare in the 4th quarter valued at about $86,000. Finally, Caitong International Asset Management Co. Ltd boosted its position in Addus HomeCare by 368.3% in the 1st quarter. Caitong International Asset Management Co. Ltd now owns 1,255 shares of the company's stock valued at $124,000 after buying an additional 987 shares during the period. Institutional investors own 95.35% of the company's stock.

Addus HomeCare Company Profile

(Get Free Report)

Addus HomeCare Corporation, together with its subsidiaries, provides personal care services to elderly, chronically ill, disabled persons, and individuals who are at risk of hospitalization or institutionalization in the United States. The company operates through three segments: Personal Care, Hospice, and Home Health.

Read More

Analyst Recommendations for Addus HomeCare (NASDAQ:ADUS)

Should You Invest $1,000 in Addus HomeCare Right Now?

Before you consider Addus HomeCare, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Addus HomeCare wasn't on the list.

While Addus HomeCare currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 Stocks Set to Soar in Summer 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

This Strategy Beat the S&P—And Most Investors Ignore It
NVDA Greenlight: China Sales Spark 50% Rally Potential
Time to Cash Out? 5 Stocks to Drop Before Earnings

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines